Feed excerpt — reported by STAT News
The FDA has to decide how and when to encourage development of exon-skipping drugs, which show promise in treating muscular dystrophy.
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →